Drugs / ASP1570
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05083481 | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Astellas Pharma Inc | Results Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 astellas.com ↗
The results support continued study of these investigational therapies for the treatment of various cancer types. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-11 | Astellas Pharma Inc | Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 astellas.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP1570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05083481 ↗ |
| Route | Oral | “Oral tablet” NCT05083481 ↗ |